Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis
- 1 October 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 98 (10), 2268-2274
- https://doi.org/10.1111/j.1572-0241.2003.07639.x
Abstract
Osteopenia increases the morbidity of primary biliary cirrhosis (PBC). In this study, we have compared two bisphosphonates, alendronate and cyclical etidronate, that inhibit osteoclast-mediated bone resorption and have examined their effects on bone mass in patients with this disease. A total of 32 women with PBC were randomly assigned to receive alendronate (10 mg/day) or etidronate (400 mg/day) for 14 days every 3 months. Bone mineral density of the lumbar spine and proximal femur were measured initially and every 6 months. Bone fractures and markers of bone mineral metabolism were also evaluated. Sixteen patients were allocated to each group, which were comparable with respect to the severity of PBC and osteopenia. Thirteen patients in each group completed the 2-yr trial. Both treatments increased bone mineral density after 2 yr, although the increase at the lumbar spine and at the proximal femur was significantly higher in patients receiving alendronate than in patients on etidronate. This higher effect of alendronate paralleled with changes in the biochemical markers of bone turnover. No patient developed new vertebral fractures, but new peripheral fractures were detected in two patients on alendronate and in one on etidronate. There were no serious adverse effects. Neither treatment impaired liver function or cholestasis. Alendronate effectively increases bone mass and has greater antiresorptive power than etidronate in patients with primary biliary cirrhosis, and is associated with minor or no side effects.Keywords
This publication has 27 references indexed in Scilit:
- Estrogen‐progestogen therapy for low bone mineral density in primary biliary cirrhosisLiver International, 1999
- Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years.Gastroenterology, 1997
- Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosisHepatology, 1994
- Management of Osteopenia of Liver Disease with Special Emphasis on Primary Biliary CirrhosisSeminars in Liver Disease, 1993
- Sodium fluoride prevents bone loss in primary biliary cirrhosisJournal of Hepatology, 1992
- Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosisHepatology, 1991
- Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatmentJournal of Hepatology, 1991
- Intermittent Cyclical Etidronate Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Effect of Intermittent Cyclical Etidronate Therapy on Bone Mass and Fracture Rate in Women with Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Metabolic bone disease in primary biliary cirrhosisJournal of Gastroenterology and Hepatology, 1990